Cancer
MimiVax vaccine misses primary endpoint in glioblastoma trial
SurVaxM did not significantly improve overall survival in the trial, though MimiVax reported a survival signal among patients 65 or younger.
MimiVax’s SurVaxM vaccine missed the primary endpoint in the randomized phase 2B SURVIVE trial in newly diagnosed glioblastoma, according to topline results reported by Healio. Among 233 evaluable patients, the vaccine did not significantly improve overall survival compared with placebo. Median overall survival was 22.8 months with SurVaxM and 20.3 months with placebo (HR = 0.75. 95% CI, 0.54-1.03).
In the prespecified subgroup aged 65 or younger, median overall survival was 24.2 months with SurVaxM and 20.2 months with placebo (HR = 0.64. 95% CI, 0.44-0.93). The vaccine group also had longer progression-free survival (HR = 0.64. P =.018). Grade 3 or higher adverse events occurred at similar rates in the SurVaxM and placebo groups, 48% vs. 46%. MimiVax CEO Michael Ciesielski said the results will support discussions with the FDA about potential regulatory next steps.
